EDSA - Edesa Biotech Inc
IEX Last Trade
4.52
0.020 0.442%
Share volume: 5,503
Last Updated: Fri 30 Aug 2024 08:37:40 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$4.50
0.02
0.44%
Fundamental analysis
20%
Profitability
18%
Dept financing
3%
Liquidity
58%
Performance
18%
Performance
5 Days
1.12%
1 Month
-10.89%
3 Months
2.27%
6 Months
-9.27%
1 Year
-23.65%
2 Year
-65.44%
Key data
Stock price
$4.52
DAY RANGE
N/A - N/A
52 WEEK RANGE
$2.46 - $8.33
52 WEEK CHANGE
-$0.23
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO:
Region: US
Website: edesabiotech.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: edesabiotech.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
founded in 2015, edesa biotech brings innovative new treatments for dermatological and anorectal diseases. late-stage prescription drugs developed by edesa biotech aim to help patients who experience limited treatment options. edesa biotech's focus on dermatology is led by an experienced team that have licensed global rights to clinical stage assets for dermatology and anorectal indications.
Recent news